A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy

Description

Caloric restriction may alter the response to chemotherapy induced stress response and enhance its antitumor effect. This study intends to use an intermitted caloric restriction protocol with alternate days before the chemotherapy administration to enhance the cytotoxic effect generated by standard treatment of cancer.

Conditions

Medical Oncology, Integrative Oncology, Medical Nutrition Therapy

Talk to us

Study Overview

On this page

Study Details

Study overview

Caloric restriction may alter the response to chemotherapy induced stress response and enhance its antitumor effect. This study intends to use an intermitted caloric restriction protocol with alternate days before the chemotherapy administration to enhance the cytotoxic effect generated by standard treatment of cancer.

A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Protein Diet in Cancer Patients Receiving Chemotherapy

A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy

Condition
Medical Oncology
Intervention / Treatment

-

Contacts and Locations

Buffalo

University at Buffalo / Great Lakes Cancer Care, Buffalo, New York, United States, 14203

Buffalo

University at Buffalo / Great Lakes Cancer Care, Buffalo, New York, United States, 14206

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * • Histologically documented, cancer patients who are eligible to receive cytotoxic chemotherapy.
  • * Life expectancy of at least 6 months
  • * Adults ≥ 18 years of age
  • * Adequate hematologic, renal, and liver function as evidenced by the following:
  • * White blood cell (WBC) ≥ 2,500 cells/μL
  • * Absolute neutrophil count (ANC) ≥ 1,000 cells/μL
  • * Platelet Count ≥ 100,000 cells/μL
  • * Hemoglobin (HgB) ≥ 9.0 g/dL
  • * Creatinine ≤ 2.0 mg/dL
  • * Total bilirubin ≤ 2 x upper limit of normal (ULN)
  • * Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN
  • * Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN
  • * • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher
  • * Treatment with any of the following medications or interventions within 28 days of registration:
  • * Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.
  • * High dose calcitriol \[1,25(OH)2VitD\] (i.e., \> 7.0 μg/week)
  • * Any infection requiring parenteral antibiotic therapy or causing fever (temperature \> 100.5°F or 38.1°C) within 1 week prior to registration
  • * A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT/MRI imaging
  • * Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

State University of New York at Buffalo,

Study Record Dates

2025-06-01